Endo sews up $9.2B financing for Par Pharma buyout

Earlier this week, Endo ($ENDP) inked a pact to nab Par Pharmaceutical for $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition. Deutsche Bank and Barclays have initially committed the financing, Reuters reports. Report | More

 

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.